Viewing nowHy’Ell 5 mg Tablet (Rosuvastatin Calcium)
Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

MFDS item code 201404241 · Approved 2014.09.17 · Insurance code 653804980
Improvement of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
This drug is used as an adjunctive therapy in patients with hypercholesterolemia and mixed dyslipidemia that are not controlled by diet and exercise. It particularly helps reduce LDL cholesterol levels in patients with primary hypercholesterolemia and familial hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is also used to effectively control cholesterol levels in pediatric patients aged between 10 and 17 with heterozygous familial hypercholesterolemia. Furthermore, it serves as an adjunct to diet for patients with abnormal beta-lipoproteinemia. Additionally, it contributes to reducing the risk of cardiovascular diseases and the risks of stroke, myocardial infarction, and vascular reintervention in men over 50 years and women over 60 years who have elevated high-sensitivity C-reactive protein levels. Overall, it improves health by managing cholesterol levels and reducing the risk of cardiovascular disease.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams once daily. 3. Elderly patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 ~ 17 years): The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goals for each patient. Adjust the dose at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.
This drug should not be administered to certain patients. For instance, it should not be used in patients who have an allergy to this drug or have active liver diseases, muscle diseases, or severe renal impairment. The use of this drug is restricted in pregnant or nursing women, or in fertile women not using appropriate contraception. It should only be administered to women of childbearing potential after confirming a low likelihood of pregnancy. High-dose administration is prohibited in patients at high risk of muscle disorders, such as those with moderate to severe renal impairment, hypothyroidism, previous history of genetic muscle disorders, and those with alcohol dependence. Furthermore, this drug contains lactose and should not be administered to patients with lactose intolerance or certain genetic metabolic disorders. Liver function tests should be conducted regularly when administering this drug, and caution should be particularly taken with patients with a history of liver disease or those consuming excessive alcohol. Muscle-related side effects such as myalgia, myopathy, and rhabdomyolysis may occur, so patients should be advised to inform healthcare professionals immediately if they experience muscle pain or weakness. This drug may increase blood concentration when taken with other specific medications, which can elevate the risk of side effects; therefore, patients must consult healthcare professionals about concomitant medications. It should not be used during pregnancy or breastfeeding, and women planning pregnancy should use appropriate contraception. In cases of overdose, there is no specific antidote, so treatment should be based on symptoms while monitoring liver function and muscle enzyme levels. The effects of this drug on the ability to drive or operate machinery are unclear, but caution is advised due to the possibility of dizziness. Finally, this drug may show higher plasma concentrations in Asians, hence dose adjustment may be needed.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, widespread pain
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain storage temperatures between 1°C and 30°C. Proper storage will help maintain the drug's effectiveness and safety.
Yellow circular film-coated tablets
28 tablets (14 tablets/PTP * 2), 30 tablets/bottle, 90 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.